AstraZeneca leukaemia drug meets trial end-point
AstraZeneca
11,988.00p
16:40 26/04/24
-0.32%
-38.00p
AstraZeneca said on Thursday its Calquence leukaemia drug had met the primary endpoint of a phase 3 trial and would allow it to file for regulatory approval later this year.
FTSE 100
8,139.83
17:09 26/04/24
n/a
n/a
FTSE 350
4,470.09
16:59 26/04/24
n/a
n/a
FTSE All-Share
4,423.59
17:14 26/04/24
n/a
n/a
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
0.10%
22.78
It said the drug showed meaningful improvement in patients with lymphocytic leukaemia when compared with a chemotherapy-based combination treatment.
Calquence in May met a primary endpoint early in a separate trial last month, AstraZeneca said in a statement.
AstraZeneca executive vice-president of oncology research and development José Baselga said the results from both trials “will serve as the foundation for regulatory submissions later this year".